ALK and non-small cell lung carcinoma: Anti-EGFR and anti-ALK targeted therapies are the frontline treatments for advanced NSCLC with EGFR mutations and ALK mutations, respectively, while platinum-based chemotherapy is the first line of treatment for advanced NSCLC without targetable mutations (1, 2).